

Fusion Biopsy Market – Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Biopsy Route (Transrectal, Transperineal), By End-User (Hospitals, Diagnostic Centers, Ambulatory Care Centers), By Region, Competition, 2019-2029F

<https://marketpublishers.com/r/F0C795AE1870EN.html>

Date: April 2024

Pages: 180

Price: US\$ 4,500.00 (Single User License)

ID: F0C795AE1870EN

Abstracts

Global Fusion Biopsy Market was valued at USD 570.01 million in 2023 and is anticipated to project impressive growth in the forecast period with a CAGR of 8.58% through 2029. Fusion biopsy, also known as targeted biopsy, combines magnetic resonance imaging (MRI) and ultrasound to guide precise and accurate biopsies. The technique is commonly employed for prostate cancer diagnosis, but it's also being explored for other conditions like liver, kidney, and breast cancer. The core concept is to use MRI images to identify suspicious areas within the body, and then fuse those images with real-time ultrasound guidance for a targeted biopsy, minimizing invasiveness and maximizing diagnostic accuracy.

Key Market Drivers

Rising Incidence of Prostate Cancer

The rising incidence of prostate cancer is a significant market driver for the growth of the Global Fusion Biopsy Market. Prostate cancer is one of the most prevalent cancers in men worldwide, and its increasing prevalence has substantial implications for the demand and adoption of fusion biopsy techniques. The global incidence of prostate cancer has been steadily increasing over the past few decades. This can be attributed to various factors, including aging populations, changing lifestyles, and improved diagnostic methods that detect prostate cancer at an earlier stage. With a larger pool of potential patients, there is a greater need for accurate and efficient diagnostic tools,

which fusion biopsy provides.

The heightened incidence of prostate cancer underscores the critical need for early diagnosis. Fusion biopsy offers an advanced, minimally invasive method for identifying and confirming the presence of prostate cancer. As healthcare providers seek to address the growing demand for prostate cancer diagnosis, fusion biopsy becomes an integral component of the diagnostic arsenal due to its precision and reliability. The rising prevalence of prostate cancer has led to an increased focus on personalized treatment strategies. Not all prostate cancers are aggressive or require the same treatment approach. Fusion biopsy helps in characterizing the cancer more accurately, differentiating between low-risk and high-risk cases. This, in turn, aids in tailoring treatment plans for patients, contributing to better clinical outcomes.

Public health initiatives and awareness campaigns have played a crucial role in educating men about the risks and benefits of prostate cancer screening. As more men become aware of the importance of early detection, they are increasingly seeking medical advice and screening. The availability of advanced diagnostic tools like fusion biopsy has enhanced their confidence in the diagnostic process, further driving demand. Medical societies and organizations have recognized the significance of early diagnosis in prostate cancer. Clinical guidelines have evolved to recommend advanced diagnostic techniques like fusion biopsy as a standard practice for certain patient groups. This endorsement by healthcare authorities bolsters the market by increasing the adoption of fusion biopsy among healthcare providers.

Advancements in Imaging Technologies

Advancements in imaging technologies play a pivotal role as a market driver for the growth of the Global Fusion Biopsy Market. Fusion biopsy, which combines magnetic resonance imaging (MRI) and ultrasound, relies heavily on these technological advancements to provide precise and real-time guidance for targeted prostate biopsies. Modern MRI and ultrasound technologies offer significantly improved imaging resolution. Higher resolution means that smaller and subtler abnormalities in the prostate can be detected and localized with greater accuracy. This is essential for identifying and targeting suspicious areas during fusion biopsies, increasing diagnostic precision.

Advancements in imaging technologies have enabled real-time imaging capabilities, which are essential for fusion biopsy procedures. Real-time MRI and ultrasound guidance allow healthcare professionals to visualize the prostate and the biopsy

needle's path as they move it. This dynamic visualization ensures that the biopsy is conducted precisely and with minimal damage to surrounding tissue. Multi-parametric MRI (mpMRI) has become a standard tool in fusion biopsy. It integrates multiple MRI sequences to provide a comprehensive assessment of the prostate, including anatomical, functional, and diffusion data. This advanced imaging technique aids in distinguishing between benign and malignant tissue, reducing false-positive and false-negative biopsy results.

The fusion of MRI and ultrasound images is a core component of fusion biopsy. Advancements in image registration and fusion software have made it easier to overlay and align MRI and ultrasound images accurately. This alignment is crucial for guiding the biopsy needle to the precise location of a suspected lesion. Imaging technologies have evolved to provide three-dimensional (3D) visualization of the prostate. This allows healthcare professionals to examine the prostate from various angles and better understand its anatomy, aiding in precise targeting of suspicious areas during the biopsy.

Minimally Invasive Procedures

Minimally invasive procedures are a significant market driver for the growth of the Global Fusion Biopsy Market. Fusion biopsy, which combines magnetic resonance imaging (MRI) and ultrasound to guide targeted prostate biopsies, aligns with the growing trend in healthcare towards less invasive diagnostic and treatment options. Minimally invasive procedures are generally associated with reduced patient discomfort and pain. Fusion biopsy, compared to traditional transrectal ultrasound-guided biopsies, is less painful and traumatic for patients. The minimally invasive nature of fusion biopsy enhances patient satisfaction and compliance with recommended diagnostic procedures.

Fusion biopsy minimizes the risk of complications associated with more invasive procedures. Traditional prostate biopsies can lead to infections, bleeding, and other adverse events. Fusion biopsy, by contrast, involves fewer needle insertions and offers a more precise and targeted approach, reducing the risk of complications. Minimally invasive procedures typically result in shorter recovery times. Patients undergoing fusion biopsies can usually return to their normal activities sooner than those undergoing more invasive procedures. This aspect is particularly appealing to individuals with busy lifestyles and work commitments.

Fusion biopsy is often performed on an outpatient basis, which means that patients can

go home the same day as the procedure. This reduces the need for hospitalization, lowers healthcare costs, and minimizes disruption to the patient's daily life. Infections, especially antibiotic-resistant infections, have become a growing concern in healthcare. Fusion biopsy minimizes the risk of infection because it involves fewer needle insertions and the use of MRI guidance to target specific areas within the prostate. This is especially relevant in an era where infection control is a priority.

Increasing Awareness and Early Detection

Increasing awareness and early detection of prostate cancer are critical market drivers for the growth of the Global Fusion Biopsy Market. This driver is deeply rooted in efforts to educate the public about the importance of early cancer detection and the advantages of fusion biopsy as a diagnostic tool. Various public health organizations and initiatives have been instrumental in raising awareness about prostate cancer and the significance of early detection. These campaigns often target men over a certain age, encouraging them to undergo regular prostate cancer screening, including PSA (prostate-specific antigen) tests and, when necessary, fusion biopsy. This heightened awareness leads to more proactive healthcare-seeking behavior. Increasing awareness equips individuals with the knowledge they need to understand the risks and benefits of prostate cancer screening. Patients become more empowered to engage in conversations with their healthcare providers, ask questions, and make informed decisions about their healthcare. This, in turn, drives the demand for early detection methods such as fusion biopsy.

Emphasizing the importance of early detection is critical in the context of prostate cancer. Detecting cancer at an early stage can lead to more effective treatments, better prognoses, and increased chances of a cure. Fusion biopsy's precision and accuracy make it an attractive choice for early detection and risk assessment, further fueling its adoption. Greater awareness of prostate cancer has led to fewer diagnoses at advanced stages, when treatment options may be limited. As more men undergo regular screenings and seek medical attention at the first sign of symptoms, the prevalence of late-stage prostate cancer decreases. This shift toward earlier-stage diagnoses underscores the need for reliable diagnostic tools like fusion biopsy. Awareness campaigns also target healthcare professionals, urging them to recommend early detection methods to eligible patients. Physicians play a crucial role in advising patients on the benefits of early detection, including the use of fusion biopsy for precise diagnosis.

Key Market Challenges

Cost Constraints

Fusion biopsy, involving the integration of advanced imaging technologies, can be relatively expensive compared to traditional biopsy methods. The cost of MRI machines, specialized software, and the additional expertise required to perform fusion biopsies can be a significant barrier. As a result, healthcare facilities may hesitate to invest in fusion biopsy equipment, and patients may be burdened with higher medical bills or face limited insurance coverage. Cost constraints can limit the adoption of fusion biopsy, particularly in regions with limited healthcare budgets or areas with a high prevalence of prostate cancer.

Access and Infrastructure

Fusion biopsy requires access to advanced medical equipment, skilled healthcare professionals, and supportive infrastructure. In many parts of the world, especially in rural or underserved areas, access to such resources can be limited. Lack of infrastructure can hinder the widespread adoption of fusion biopsy, leading to disparities in healthcare quality. Furthermore, even in regions with advanced healthcare systems, there may be a shortage of skilled practitioners who can effectively perform fusion biopsies, further limiting its availability.

Regulatory and Reimbursement Challenges

Regulatory approval and reimbursement policies can significantly impact the adoption of fusion biopsy. The process of gaining regulatory approval for new medical technologies can be time-consuming and costly. Additionally, the lack of standardized reimbursement policies or low reimbursement rates can discourage healthcare providers from offering fusion biopsy services. This can be particularly challenging for smaller medical practices or clinics that rely heavily on insurance reimbursements. The uncertainty regarding reimbursement can deter healthcare facilities from investing in fusion biopsy technology and providing it to their patients.

Key Market Trends

Rising Demand for Personalized Medicine

One of the prominent trends in the fusion biopsy market is the increasing demand for personalized medicine. Patients and healthcare providers are seeking more

individualized approaches to cancer diagnosis and treatment. Fusion biopsy, with its ability to provide detailed and precise information about the location and aggressiveness of prostate cancer, aligns with this trend. It enables physicians to tailor treatment plans to the specific needs of each patient, avoiding overtreatment in low-risk cases and ensuring aggressive treatment in high-risk cases. This trend not only improves patient outcomes but also drives the adoption of fusion biopsy as a vital tool for delivering personalized care.

Integration of Artificial Intelligence (AI) and Machine Learning

Another major trend in the fusion biopsy market is the integration of artificial intelligence (AI) and machine learning. AI technologies are being used to enhance the interpretation of imaging data from MRI and ultrasound scans. Machine learning algorithms can aid in the detection and characterization of suspicious lesions within the prostate, making fusion biopsy procedures even more accurate and efficient. These technologies not only improve the diagnostic process but also have the potential to reduce the workload on healthcare professionals and increase the consistency and reproducibility of results. The fusion of AI with fusion biopsy is expected to drive innovation and further improve the diagnostic capabilities of this technology.

Expanding Applications Beyond Prostate Cancer

While fusion biopsy's primary application is in prostate cancer diagnosis, a notable trend is its expansion into the diagnosis and treatment of other cancers and medical conditions. The precision and real-time imaging capabilities of fusion biopsy are being explored in areas such as liver, kidney, and breast cancer, as well as neurological and musculoskeletal disorders. This diversification of applications broadens the market's scope and potential, as healthcare providers look to leverage the benefits of fusion biopsy in various medical specialties. This trend also spurs research and development in adapting fusion biopsy technology for different clinical applications.

Segmental Insights

Biopsy Route Insights

Based on the category of Biopsy Route, the Transrectal segment emerged as the dominant player in the global market for Fusion Biopsy in 2023. Transrectal biopsy has been a well-established and widely used method for prostate cancer diagnosis for several decades. Physicians and urologists have significant experience with this route,

making it the default choice for many healthcare providers. This historical prevalence and familiarity give the Transrectal segment a significant advantage, as medical professionals tend to stick with methods, they are comfortable with.

Transrectal biopsy is relatively accessible and can be performed in various healthcare settings, including outpatient clinics and hospitals. This convenience makes it the go-to option for many patients and physicians. Fusion biopsy, when performed transrectally, builds upon the existing infrastructure and workflow, ensuring minimal disruption to established diagnostic routines.

Despite its invasiveness, many patients are more comfortable with the transrectal route for prostate biopsy, as it is perceived as less intimidating compared to alternative routes. This patient comfort and acceptance are crucial factors in the choice of biopsy route and contribute to the dominance of the Transrectal segment. Transrectal biopsy is effective in obtaining samples from the prostate, which is critical for diagnosing prostate cancer accurately. The approach allows for the sampling of multiple areas of the prostate, providing a comprehensive assessment of the organ. This effectiveness in tissue sampling makes Transrectal fusion biopsy a trusted method for diagnosing prostate cancer. These factors are expected to drive the growth of this segment.

End-User Insights

The hospital segment is projected to experience rapid growth during the forecast period. Hospitals typically house a wide range of medical specialists, including urologists and radiologists, who are key players in the diagnosis and treatment of prostate cancer, the primary application for fusion biopsy. The expertise of these specialists is crucial for performing and interpreting fusion biopsy procedures accurately. Hospitals often have a larger pool of specialized healthcare professionals, which makes them well-equipped to offer fusion biopsy services. Fusion biopsy relies on advanced imaging technologies, particularly MRI and ultrasound. Hospitals are more likely to possess state-of-the-art imaging equipment, which is essential for the precision and reliability of fusion biopsy. The high cost of MRI machines and the need for specialized software and maintenance mean that hospitals are better positioned to invest in and maintain these resources.

Hospitals typically offer comprehensive healthcare services, from initial screenings and diagnostic tests to treatment and follow-up care. This integrated approach is beneficial in the context of fusion biopsy, as it ensures a seamless transition from diagnosis to treatment. The continuity of care provided by hospitals enhances patient experience and improves the effectiveness of fusion biopsy as a diagnostic tool. Hospitals often

have strong affiliations with academic and research institutions. This academic environment encourages research and development activities related to fusion biopsy and allows for the incorporation of the latest advancements into clinical practice. Hospitals serve as hubs for medical innovation, ensuring that fusion biopsy procedures remain on the cutting edge of diagnostic technologies. These factors collectively contribute to the growth of this segment.

Regional Insights

North America emerged as the dominant player in the global Fusion Biopsy market in 2023, holding the largest market share in terms of both value and volume. North America boasts a highly developed and advanced healthcare infrastructure. This includes a wide network of hospitals, clinics, and diagnostic centers equipped with cutting-edge medical technologies. Fusion biopsy, which requires sophisticated imaging equipment and specialized expertise, is more readily available in this region. Prostate cancer is a significant health concern in North America, with a high incidence rate. The prevalence of this cancer drives the demand for accurate and reliable diagnostic tools like fusion biopsy. Given the emphasis on early detection and treatment, fusion biopsy plays a crucial role in the region's healthcare system. North America has a substantial pool of skilled healthcare professionals, including urologists and radiologists, who are essential for performing and interpreting fusion biopsy procedures accurately. The availability of specialized expertise contributes to the widespread adoption of fusion biopsy. The region is at the forefront of research and development in medical technologies. Ongoing innovation and technological advancements in the field of fusion biopsy ensure that North America remains a leader in the market. Academic and research institutions collaborate with healthcare facilities, driving continuous improvement in fusion biopsy technology. North America has established reimbursement policies and insurance coverage for fusion biopsy, making it more accessible and affordable for patients. This financial support encourages the adoption of fusion biopsy as a preferred diagnostic method.

The Europe market is poised to be the fastest-growing market, offering lucrative growth opportunities for Fusion Biopsy players during the forecast period. Factors such as Europe have seen a surge in awareness campaigns and initiatives promoting early cancer detection. Prostate cancer awareness and screening programs have gained momentum, leading to an increased number of patients seeking diagnostic services, including fusion biopsy. Europe has been investing in upgrading its healthcare infrastructure, particularly in countries with advanced healthcare systems. The acquisition of modern imaging equipment and the expansion of healthcare facilities

contribute to the growth of fusion biopsy services. Like North America, Europe is also experiencing a rise in prostate cancer incidence. This growing health concern underscores the importance of early and accurate diagnosis, driving the demand for fusion biopsy as a reliable diagnostic tool. European healthcare providers are increasingly embracing innovative medical technologies. Fusion biopsy, with its precision and non-invasiveness, aligns with the region's focus on enhancing patient care and treatment outcomes.

Key Market Players

Eigen Health Ltd

Koninklijke Philips N.V.

Hitachi, Ltd.

MedCom Inc

Esaoate SpA

KOELIS SAS

Focal Healthcare Inc

UC-Care Medical Systems Ltd.

GeoScan Medical

Report Scope:

In this report, the Global Fusion Biopsy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Fusion Biopsy Market,By Biopsy Route:

oTransrectal

oTransperineal

Fusion Biopsy Market,By End-User:

- oHospitals

- oDiagnostic Centers

- oAmbulatory Care Centers

Fusion Biopsy Market, By Region:

- oNorth America

 - United States

 - Canada

 - Mexico

- oEurope

 - France

 - United Kingdom

 - Italy

 - Germany

 - Spain

- oAsia-Pacific

 - China

 - India

 - Japan

Australia

South Korea

oSouth America

Brazil

Argentina

Colombia

oMiddle East Africa

South Africa

Saudi Arabia

UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Fusion Biopsy Market.

Available Customizations:

Global Fusion Biopsy market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Contents

1.PRODUCT OVERVIEW

- 1.1.Market Definition
- 1.2.Scope of the Market
 - 1.2.1.Markets Covered
 - 1.2.2.Years Considered for Study
 - 1.2.3.Key Market Segmentations

2.RESEARCH METHODOLOGY

- 2.1.Objective of the Study
- 2.2.Baseline Methodology
- 2.3.Key Industry Partners
- 2.4.Major Association and Secondary Sources
- 2.5.Forecasting Methodology
- 2.6.Data Triangulation Validation
- 2.7.Assumptions and Limitations

3.EXECUTIVE SUMMARY

- 3.1.Overview of the Market
- 3.2.Overview of Key Market Segmentations
- 3.3.Overview of Key Market Players
- 3.4.Overview of Key Regions/Countries
- 3.5.Overview of Market Drivers, Challenges, Trends

4.VOICE OF CUSTOMER

5.GLOBALFUSION BIOPSY MARKETOUTLOOK

- 5.1.Market Size Forecast
 - 5.1.1.By Value
- 5.2.Market Share Forecast
 - 5.2.1.By Biopsy Route (Transrectal, Transperineal)
 - 5.2.2.By End-User (Hospitals, Diagnostic Centers, Ambulatory Care Centers)
 - 5.2.3.By Region
 - 5.2.4.By Company (2023)

5.3. Market Map

6. NORTH AMERICA FUSION BIOPSY MARKET OUTLOOK

6.1. Market Size Forecast

6.1.1. By Value

6.2. Market Share Forecast

6.2.1. By Biopsy Route

6.2.2. By End-User

6.2.3. By Country

6.3. North America: Country Analysis

6.3.1. United States Fusion Biopsy Market Outlook

6.3.1.1. Market Size Forecast

6.3.1.1.1. By Value

6.3.1.2. Market Share Forecast

6.3.1.2.1. By Biopsy Route

6.3.1.2.2. By End-User

6.3.2. Canada Fusion Biopsy Market Outlook

6.3.2.1. Market Size Forecast

6.3.2.1.1. By Value

6.3.2.2. Market Share Forecast

6.3.2.2.1. By Biopsy Route

6.3.2.2.2. By End-User

6.3.3. Mexico Fusion Biopsy Market Outlook

6.3.3.1. Market Size Forecast

6.3.3.1.1. By Value

6.3.3.2. Market Share Forecast

6.3.3.2.1. By Biopsy Route

6.3.3.2.2. By End-User

7. EUROPE FUSION BIOPSY MARKET OUTLOOK

7.1. Market Size Forecast

7.1.1. By Value

7.2. Market Share Forecast

7.2.1. By Biopsy Route

7.2.2. By End-User

7.2.3. By Country

7.3. Europe: Country Analysis

7.3.1.Germany Fusion Biopsy Market Outlook

7.3.1.1.Market Size Forecast

7.3.1.1.1.By Value

7.3.1.2.Market Share Forecast

7.3.1.2.1.By Biopsy Route

7.3.1.2.2.By End-User

7.3.2.United Kingdom Fusion Biopsy Market Outlook

7.3.2.1.Market Size Forecast

7.3.2.1.1.By Value

7.3.2.2.Market Share Forecast

7.3.2.2.1.By Biopsy Route

7.3.2.2.2.By End-User

7.3.3.Italy Fusion Biopsy Market Outlook

7.3.3.1.Market Size Forecast

7.3.3.1.1.By Value

7.3.3.2.Market Share Forecast

7.3.3.2.1.By Biopsy Route

7.3.3.2.2.By End-User

7.3.4.France Fusion Biopsy Market Outlook

7.3.4.1.Market Size Forecast

7.3.4.1.1.By Value

7.3.4.2.Market Share Forecast

7.3.4.2.1.By Biopsy Route

7.3.4.2.2.By End-User

7.3.5.Spain Fusion Biopsy Market Outlook

7.3.5.1.Market Size Forecast

7.3.5.1.1.By Value

7.3.5.2.Market Share Forecast

7.3.5.2.1.By Biopsy Route

7.3.5.2.2.By End-User

8.ASIA-PACIFIC FUSION BIOPSY MARKET OUTLOOK

8.1.Market Size Forecast

8.1.1.By Value

8.2.Market Share Forecast

8.2.1.By Biopsy Route

8.2.2.By End-User

8.2.3. By Country

8.3.Asia-Pacific: Country Analysis

8.3.1.China Fusion Biopsy Market Outlook

8.3.1.1.Market Size Forecast

8.3.1.1.1.By Value

8.3.1.2.Market Share Forecast

8.3.1.2.1.By Biopsy Route

8.3.1.2.2.By End-User

8.3.2.India Fusion Biopsy Market Outlook

8.3.2.1.Market Size Forecast

8.3.2.1.1.By Value

8.3.2.2.Market Share Forecast

8.3.2.2.1.By Biopsy Route

8.3.2.2.2.By End-User

8.3.3.Japan Fusion Biopsy Market Outlook

8.3.3.1.Market Size Forecast

8.3.3.1.1.By Value

8.3.3.2.Market Share Forecast

8.3.3.2.1.By Biopsy Route

8.3.3.2.2.By End-User

8.3.4.South Korea Fusion Biopsy Market Outlook

8.3.4.1.Market Size Forecast

8.3.4.1.1.By Value

8.3.4.2.Market Share Forecast

8.3.4.2.1.By Biopsy Route

8.3.4.2.2.By End-User

8.3.5.Australia Fusion Biopsy Market Outlook

8.3.5.1.Market Size Forecast

8.3.5.1.1.By Value

8.3.5.2.Market Share Forecast

8.3.5.2.1.By Biopsy Route

8.3.5.2.2.By End-User

9.SOUTH AMERICA FUSION BIOPSY MARKET OUTLOOK

9.1.Market Size Forecast

9.1.1.By Value

9.2.Market Share Forecast

9.2.1.By Biopsy Route

9.2.2.By End-User

9.2.3. By Country

9.3. South America: Country Analysis

9.3.1. Brazil Fusion Biopsy Market Outlook

9.3.1.1. Market Size Forecast

9.3.1.1.1. By Value

9.3.1.2. Market Share Forecast

9.3.1.2.1. By Biopsy Route

9.3.1.2.2. By End-User

9.3.2. Argentina Fusion Biopsy Market Outlook

9.3.2.1. Market Size Forecast

9.3.2.1.1. By Value

9.3.2.2. Market Share Forecast

9.3.2.2.1. By Biopsy Route

9.3.2.2.2. By End-User

9.3.3. Colombia Fusion Biopsy Market Outlook

9.3.3.1. Market Size Forecast

9.3.3.1.1. By Value

9.3.3.2. Market Share Forecast

9.3.3.2.1. By Biopsy Route

9.3.3.2.2. By End-User

10. MIDDLE EAST AND AFRICA FUSION BIOPSY MARKET OUTLOOK

10.1. Market Size Forecast

10.1.1. By Value

10.2. Market Share Forecast

10.2.1. By Biopsy Route

10.2.2. By End-User

10.2.3. By Country

10.3. MEA: Country Analysis

10.3.1. South Africa Fusion Biopsy Market Outlook

10.3.1.1. Market Size Forecast

10.3.1.1.1. By Value

10.3.1.2. Market Share Forecast

10.3.1.2.1. By Biopsy Route

10.3.1.2.2. By End-User

10.3.2. Saudi Arabia Fusion Biopsy Market Outlook

10.3.2.1. Market Size Forecast

10.3.2.1.1. By Value

10.3.2.2. Market Share Forecast

10.3.2.2.1. By Biopsy Route

10.3.2.2.2. By End-User

10.3.3. UAE Fusion Biopsy Market Outlook

10.3.3.1. Market Size Forecast

10.3.3.1.1. By Value

10.3.3.2. Market Share Forecast

10.3.3.2.1. By Biopsy Route

10.3.3.2.2. By End-User

11. MARKET DYNAMICS

11.1. Drivers

11.2. Challenges

12. MARKET TRENDS DEVELOPMENTS

12.1. Recent Developments

12.2. Product Launches

12.3. Mergers Acquisitions

13. GLOBAL FUSION BIOPSY MARKET: SWOT ANALYSIS

14. COMPETITIVE LANDSCAPE

14.1. Eigen Health Ltd

14.1.1. Business Overview

14.1.2. Product Service Offerings

14.1.3. Recent Developments

14.1.4. Key Personnel

14.1.5 SWOT Analysis

14.2. Koninklijke Philips N.V.

14.3. Hitachi, Ltd.

14.4. MedCom Inc

14.5. Esaoate SpA

14.6. KOELIS SAS

14.7. Focal Healthcare Inc

14.8. UC-Care Medical Systems Ltd.

14.9. GeoScan Medical

15.STRATEGIC RECOMMENDATIONS

16.ABOUT US DISCLAIMER

I would like to order

Product name: Fusion Biopsy Market – Global Industry Size, Share, Trends, Opportunity, & Forecast, Segmented By Biopsy Route (Transrectal, Transperineal), By End-User (Hospitals, Diagnostic Centers, Ambulatory Care Centers), By Region, Competition, 2019-2029F

Product link: <https://marketpublishers.com/r/F0C795AE1870EN.html>

Price: US\$ 4,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/F0C795AE1870EN.html>